Breaking News

WuXi PharmaTech, PBI In Biomarker Alliance

By Kristin Brooks | March 11, 2014

Gains access to PBI’s biomarker assays to support clinical testing services

WuXi PharmaTech and Pacific Biomarkers (PBI) have entered a collaboration under which PBI will provide access to its portfolio of validated biomarker assays to support WuXi's clinical trial testing services, including bioanalysis and central lab services for pharma and biopharma companies performing clinical trials in China.

PBI’s biomarkers include therapeutics areas of cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.

"We are very pleased to reach this agreement with Pacific Biomarkers, which broadens WuXi's biomarker capabilities in support of our clients' clinical development," said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. "Biomarkers are a new and important tool in the development of personalized medicines for many serious diseases."

"Partnering with WuXi enables us to realize considerable value in our biomarker assets," said Ronald Helm, chief executive officer of Pacific Biomarkers. "This agreement will allow us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016